Patients with chronic spontaneous urticaria had positive outcomes weeks after barzolvolimab, according to data presented at ...
Barzolvolimab improved symptoms in chronic spontaneous urticaria, supporting mast cell targeting as a novel treatment strategy. Read more.
As previously reported in the Phase 2 ColdU and SD study, up to 53% of patients with ColdU and 58% with SD achieved complete response (negative provocation test) at Week 12 (primary endpoint analysis) ...
Certain immune cells backstab their cellular coworkers during allergic reactions. Mast cells, the security patrols of the immune system, can trigger allergic inflammation when they run into unfamiliar ...
Detailed price information for Celldex Therapeutics (CLDX-Q) from The Globe and Mail including charting and trades.
Depending on one's perspective, "mast cell activation syndrome (MCAS)" is either a relatively rare, narrowly defined severe allergic condition or a vastly under-recognized underlying cause of multiple ...
Association of resting mast cell infiltration in the sarcoma microenvironment with overall survival.
Vitamin D serum level as a predictor of response to immunotherapy for non-small cell lung cancer. Effect of genetically engineered Salmonella typhimurium secreting conantokin G on PD-L1 antibody ...
According to an international multicenter study, CD2-negative mast cells are associated with significantly reduced overall survival in patients with SM. Patients with CD2-negative mast cells have ...
Magnetoelectric nanoparticles embedded in a hydrogel and delivered by a threaded acupuncture needle activate mast cells under ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results